R&D Trends 2012 – Pharmaceutical Companies use Externalization & Collaboration to Drive Growth
DALLAS, May 21, 2012 /PRNewswire/ –
ReportsnReports.com adds new market research reports on “R&D Trends 2012″ to its
store. Mounting pressure to reduce the cost of R&D and boost productivity has resulted in
pharma companies undertaking radical strategies as the search for efficiency continues.
With the ongoing patent cliff triggering a wave of patent expiries, pharmaceutical R&D
[http://www.reportsnreports.com/reports/160648-rd-trends-2012.html ] is at a turning
As a short-term solution to increase profitability, the numerous companies have
slashed their budgets, including R&D investment, but in the long term, downsizing may not
prove to be sustainable, and as a result companies are placing a greater focus on
Externalization has become a core strategy in order to overcome R&D challenges, with
companies opting to source their drug candidates via M&A, collaborations,
licensing/co-development deals, venture capital investments, and partnerships with
universities, spreading the cost and risk of drug development.
Pharma companies have re-evaluated their R&D pipelines in recent years, focusing on
high growth, niche areas, while deprioritizing areas with low unmet meet. Consequently,
leading pharma companies are focusing on developing candidates for secondary care
indications while simultaneously reducing their efforts in primary care diseases.
Features and Benefits:
- Provides an overview of the key R&D challenges facing pharma today as well as pharma's solutions to alleviate these pressures. - Trend analysis of R&D metrics, both industry wide and on a case-by-case basis for key Big Pharma companies. - Insight into pharma's R&D externalization strategies, supported by case study analysis. - Case study analysis comparing and contrasting the performance and clinical pipelines AstraZeneca, Pfizer, Roche, and Sanofi.
Buy your copy of this report @
Your key questions answered
- What are the key R&D challenges facing pharma today? - What strategies is the industry employing to alleviate pressures on R&D? - What types of externalization strategies are pharma companies using to bolster the clinical pipelines? - What are the key drivers and strategies that have shaped the clinical pipelines of leading pharma players?
List of Tables in this report
- Table: Staff lay-offs by leading pharma companies, 2011 - Table: US new molecular entity and Biologic License Application approvals, 2011 - Table: Notable industry-academia partnerships announced during 2011-12 - Table: Pharma's corporate venture capital businesses - Table: Notable corporate venture capital deals completed, 2011-12 - Table: Currency exchange rates, 2011
List of Figures in this report
- Figure: The relationship between pharma's strategic responses to boost R&D productivity - Figure: Drivers and resistors for global sales growth of prescription products for the leading pharma companies, as well as their strategic responses, 2011-16 - Figure: Global R&D spend and new drug approvals, 1990-2010 - Figure: The growing cost of drug discovery and allocation of R&D investment, by function (%), 2010 vs. 2011 - Figure: The principal goal of adaptive design: faster and shorter clinical trials - Figure: Advantages and disadvantages of adaptive clinical trials - Figure: R&D productivity for the top 10 R&D budgets, 2011 - Figure: Classification of economic evaluations according to the method of data collection - Figure: Pharma has had to grapple with growing regulatory pressures - Figure: New molecular entities and Biologic License Applications approved by the FDA's Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research, 2005-11 - Figure: Combined global prescription sales for the top 40 branded pharma companies, by product source ($bn), 2003-16 - Figure: Sales growth for leading branded pharma companies, by product source, 2011-16 - Figure: The relationship between pharma's strategic responses to boost R&D productivity - Figure: Venture capital investment in the US biotechnology sector, 1995-2011 - Figure: Key drivers and resistors facing licensees and licensors in the pharmaceutical industry - Figure: Two types of M&A models reflect different company growth strategies - Figure: Abbott's new corporate structure - separation into two companies - Figure: Drivers and resistors for global sales growth of prescription products for the leading pharma companies, as well as their strategic responses, 2011-16 - Figure: Forecast sales growth ($bn), 2012-16 - Figure: Number of drug candidates in clinical development (Phase I, II, and III) for AstraZeneca, Pfizer, Sanofi, and Roche, 2007 vs. 2011 - Figure: Number of drug candidates in clinical development (Phase I, II and III) according to indication for AstraZeneca, Roche, Sanofi and Pfizer only, 2007 vs. 2011 - Figure: Sales growth (by primary indication only) for the leading pharma companies, 2010-16 - Figure: Proportion of drug candidates in clinical development that are externally sourced (%), 2007 vs. 2011 - Figure: Roche's R&D pipeline (Phase I, II and III), 2007 vs. 2011 - Figure: Sanofi's R&D pipeline (Phase I, II, and III), 2007 vs. 2011 - Figure: Pfizer's R&D pipeline (Phase I, II, and III), 2007 vs. 2011 - Figure: AstraZeneca's R&D pipeline (Phase I, II, and III), 2007 vs. 2011
Find other newly published market research reports @
ReportsnReports.com [http://www.reportsnreports.com ] is an online market research
reports library of 175,000+ in-depth studies of over 5000 micro markets. Our database
includes reports by leading publishers from across the globe. We provide 24/7 online and
offline support service to our customers.
Contact: Priyank Tiwari TX, Dallas North - Dominion Plaza, 17304, Preston Road, Suite 800, Dallas 75252 Tel: +1-888-391-5441 email@example.com Explore China Specific Market Research Reports @ http://marketreportschina.com